Matches in Wikidata for { <http://www.wikidata.org/entity/Q66390319> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q66390319 description "clinical trial" @default.
- Q66390319 description "ensayu clínicu" @default.
- Q66390319 description "klinisch onderzoek" @default.
- Q66390319 description "клінічне випробування" @default.
- Q66390319 description "կլինիկական փորձարկում" @default.
- Q66390319 name "Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone" @default.
- Q66390319 name "Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone" @default.
- Q66390319 type Item @default.
- Q66390319 label "Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone" @default.
- Q66390319 label "Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone" @default.
- Q66390319 prefLabel "Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone" @default.
- Q66390319 prefLabel "Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone" @default.
- Q66390319 P1050 Q66390319-AAB23F59-1143-4521-A5B0-DDC5ABCC988B @default.
- Q66390319 P1132 Q66390319-B1489748-54BE-4F3E-9ACB-60CFD7E76BEF @default.
- Q66390319 P1476 Q66390319-FA6DBF1D-5535-4B49-BE18-BA5BD0374C9F @default.
- Q66390319 P17 Q66390319-B9CF7E48-687D-4D2D-9827-C0A31459C5F6 @default.
- Q66390319 P2899 Q66390319-0ECA744F-D52A-4883-BCF5-7B8CB164727B @default.
- Q66390319 P3098 Q66390319-305C25EB-E775-4D7E-84EF-065AE0F49386 @default.
- Q66390319 P31 Q66390319-0376C4BE-DE7B-4A13-8841-BF7F7AAEDE0D @default.
- Q66390319 P4844 Q66390319-2A62D5A0-9376-4119-8CC5-ADDB7E59A555 @default.
- Q66390319 P4844 Q66390319-8E1C3A8E-FDD3-4CB4-980C-BBC82705A007 @default.
- Q66390319 P580 Q66390319-64C9C4E4-3911-443D-9369-9353978622BC @default.
- Q66390319 P582 Q66390319-D4DE9F37-3008-4E7A-8A93-CD0105F62656 @default.
- Q66390319 P6099 Q66390319-52450DA8-29FA-41AF-A2FD-72DE1896882D @default.
- Q66390319 P8363 Q66390319-E9A6506F-4F77-4018-AE9C-53FEA06D79E3 @default.
- Q66390319 P1050 Q467635 @default.
- Q66390319 P1132 "+153" @default.
- Q66390319 P1476 "Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients" @default.
- Q66390319 P17 Q183 @default.
- Q66390319 P2899 "+18" @default.
- Q66390319 P3098 "NCT03104842" @default.
- Q66390319 P31 Q30612 @default.
- Q66390319 P4844 Q408524 @default.
- Q66390319 P4844 Q425681 @default.
- Q66390319 P580 "2017-08-15T00:00:00Z" @default.
- Q66390319 P582 "2023-07-01T00:00:00Z" @default.
- Q66390319 P6099 Q42824440 @default.
- Q66390319 P8363 Q78089383 @default.